We expect a more open regulatory environment, said Samina Vaziralli, executive chairperson, Cipla in her first-ever television interview.
She said, "(We) Expect a much more open regulatory environment in terms of the way drugs are approved. We have seen a lot of reform on the whole clinical trial piece and that is positive for the industry."Speaking about succession plan, she said, “I have been entrusted with the responsibility by the founding family to take Cipla’s legacy forward. So in my role as effective vice-chairperson, I am the only family member in an executive role and this is about the responsibility about taking this legacy forward.”